TheraCea Pharma

Clinical product for early assessment of efficacy of immunotherapy drugs to save time, money, and lives.

Validation studies in animal and initiating regulatory related activities

Immunotherapy drugs (cancer vaccines, CAR-T, monoclonal antibodies, and checkpoint inhibitors) are highly effective and promising for the treatment of cancer. But, unfortunately, they only works in less than 20% of the total population of the cancer patients. There is no reliable clinical diagnosis for early assessment of efficacy of immunotherapy treatment, which leads to: 1) a life-threatening delay to adopt alternative treatments, 2) significant cost for the patients and the healthcare system, and 3) inconclusive, longer, and more expensive clinical trials for new immunotherapy products.

TheraCea is developing a clinical diagnostic product for the early assessment of patient response to cancer immunotherapy drugs by Positron Emission Tomography (PET) imaging. This product offers significant technical and economic advantages, access to a large distribution network, and adoptability with the current infrastructure in the industry.

While the product is in the clinical trials stages, it will be used as a service for other pharmaceutical companies during their clinical trials on immunotherapy product. Later when the product is in the market, it will use to identify the right group of patients for specific immunotherapy drugs

National NSF ICorps program, NIH C3i training, University of Arizona Center for Innovation incubator program